Profilo
Shirley M.
Clift worked as Vice President-Regulatory Affairs at Cell Genesys, Inc. from 1997 to 2009 and at Sangamo Therapeutics, Inc. from 2010 to 2019.
She obtained an undergraduate degree from the University of California, Berkeley.
Precedenti posizioni note di Shirley M. Clift
Società | Posizione | Fine |
---|---|---|
SANGAMO THERAPEUTICS, INC. | Consigliere Generale | 01/01/2019 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Consigliere Generale | 01/01/2009 |
Formazione di Shirley M. Clift
University of California, Berkeley | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
SANGAMO THERAPEUTICS, INC. | Health Technology |
Aziende private | 1 |
---|---|
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
- Borsa valori
- Insiders
- Shirley M. Clift